© 2020 MJH Life Sciences and . All rights reserved.
EXAM: Cabozantinib Doubled Survival in Medullary Thyroid Carcinoma With RET M918T Mutation
June 10, 2015
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
In this video, Steven I. Sherman, MD, of the MD Anderson Cancer Center in Houston, Texas, discusses the final overall survival analysis of EXAM, a randomized, placebo-controlled phase III trial studying cabozantinib in patients with progressive, locally advanced, or metastatic medullary thyroid carcinoma.